JP2020509031A5 - - Google Patents

Download PDF

Info

Publication number
JP2020509031A5
JP2020509031A5 JP2019547310A JP2019547310A JP2020509031A5 JP 2020509031 A5 JP2020509031 A5 JP 2020509031A5 JP 2019547310 A JP2019547310 A JP 2019547310A JP 2019547310 A JP2019547310 A JP 2019547310A JP 2020509031 A5 JP2020509031 A5 JP 2020509031A5
Authority
JP
Japan
Prior art keywords
preparation according
monoclonal antibody
seq
concentration
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019547310A
Other languages
English (en)
Japanese (ja)
Other versions
JP7046088B2 (ja
JP2020509031A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/020264 external-priority patent/WO2018160722A1/en
Publication of JP2020509031A publication Critical patent/JP2020509031A/ja
Publication of JP2020509031A5 publication Critical patent/JP2020509031A5/ja
Priority to JP2022045862A priority Critical patent/JP7446356B2/ja
Application granted granted Critical
Publication of JP7046088B2 publication Critical patent/JP7046088B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019547310A 2017-03-01 2018-02-28 抗ｒｓｖモノクローナル抗体製剤 Active JP7046088B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022045862A JP7446356B2 (ja) 2017-03-01 2022-03-22 抗ｒｓｖモノクローナル抗体製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762465379P 2017-03-01 2017-03-01
US62/465,379 2017-03-01
PCT/US2018/020264 WO2018160722A1 (en) 2017-03-01 2018-02-28 Anti-rsv monoclonal antibody formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022045862A Division JP7446356B2 (ja) 2017-03-01 2022-03-22 抗ｒｓｖモノクローナル抗体製剤

Publications (3)

Publication Number Publication Date
JP2020509031A JP2020509031A (ja) 2020-03-26
JP2020509031A5 true JP2020509031A5 (enExample) 2021-03-04
JP7046088B2 JP7046088B2 (ja) 2022-04-01

Family

ID=61903153

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019547310A Active JP7046088B2 (ja) 2017-03-01 2018-02-28 抗ｒｓｖモノクローナル抗体製剤
JP2022045862A Active JP7446356B2 (ja) 2017-03-01 2022-03-22 抗ｒｓｖモノクローナル抗体製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022045862A Active JP7446356B2 (ja) 2017-03-01 2022-03-22 抗ｒｓｖモノクローナル抗体製剤

Country Status (24)

Country Link
US (4) US10774133B2 (enExample)
EP (1) EP3589648A4 (enExample)
JP (2) JP7046088B2 (enExample)
KR (2) KR102668158B1 (enExample)
CN (3) CN110418803B (enExample)
AR (1) AR111083A1 (enExample)
AU (2) AU2018227502B2 (enExample)
BR (1) BR112019017755A2 (enExample)
CA (1) CA3051864A1 (enExample)
CL (1) CL2019002478A1 (enExample)
CO (1) CO2019009034A2 (enExample)
CR (1) CR20190400A (enExample)
EA (1) EA201991701A1 (enExample)
EC (1) ECSP19062769A (enExample)
GB (1) GB2564175B (enExample)
IL (2) IL268202B2 (enExample)
MX (1) MX2019010408A (enExample)
MY (1) MY206022A (enExample)
PH (1) PH12019501979A1 (enExample)
SG (1) SG11201906853QA (enExample)
TW (2) TWI911431B (enExample)
UA (1) UA128450C2 (enExample)
WO (1) WO2018160722A1 (enExample)
ZA (1) ZA202006797B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
KR102188437B1 (ko) 2014-01-15 2020-12-08 메디뮨 엘엘씨 Rsv 특이적 항체 및 이의 기능적 부위
EP3383435A4 (en) * 2015-11-30 2019-07-10 Medimmune, LLC OPTIMIZED RATES OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS HAVING HIGH CONCENTRATIONS IN PROTEIN-BASED THERAPEUTICS
TWI911431B (zh) * 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
BR112019018022A2 (pt) * 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
CN113056482A (zh) 2018-10-18 2021-06-29 默沙东公司 抗rsv抗体的制剂及其使用方法
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
CN113993884A (zh) * 2019-04-18 2022-01-28 弗劳恩霍夫应用研究促进协会 抑制呼吸道合胞病毒感染的生物及合成分子
US12024553B2 (en) * 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies
MX2022011892A (es) 2020-03-26 2022-10-18 Univ Vanderbilt Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del sindrome respiratorio agudo grave (sars-cov-2).
CA3190474A1 (en) * 2020-07-31 2022-02-03 Alamab Therapeutics, Inc. Anti-connexin antibody formulations
CN115960214A (zh) * 2021-10-12 2023-04-14 中国科学院分子细胞科学卓越创新中心 中和呼吸道合胞病毒的全人抗体的设计及应用
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
CN119264248A (zh) * 2022-07-22 2025-01-07 北京智仁美博生物科技有限公司 抗呼吸道合胞病毒中和性抗体及其用途
CN119546630A (zh) * 2022-12-08 2025-02-28 南京诺唯赞生物科技股份有限公司 特异性结合rsv的抗体

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
ATE194291T1 (de) 1995-09-18 2000-07-15 Intracel Corp Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
ES2392073T3 (es) * 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
AU2013201261B2 (en) 2002-06-14 2016-06-23 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AU2004229335C1 (en) * 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
EP1998799B8 (en) * 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
AU2009311287C1 (en) 2008-11-05 2015-02-19 Merck Sharp & Dohme Corp. Live, attentuated respiratory syncytial virus
EP2458990B1 (en) * 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
AU2009353693B2 (en) 2009-10-06 2016-07-21 Medimmune Ltd RSV-specific binding molecule
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CL2011003002A1 (es) 2011-11-25 2012-05-25 Univ Pontificia Catolica Chile Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento.
EP4527855A3 (en) * 2012-03-26 2025-06-11 Sanofi Stable igg4 based binding agent formulations
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
ES2778899T3 (es) 2013-02-01 2020-08-12 Medimmune Llc Epítopos de proteína F del virus sincitial respiratorio
KR102188437B1 (ko) 2014-01-15 2020-12-08 메디뮨 엘엘씨 Rsv 특이적 항체 및 이의 기능적 부위
KR20170065662A (ko) * 2014-10-18 2017-06-13 화이자 인코포레이티드 항-il-7r 항체 조성물
CA2991002C (en) * 2015-07-07 2023-11-28 Janssen Vaccines & Prevention B.V. Vaccine against rsv
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
TWI911431B (zh) * 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
BR112019018022A2 (pt) * 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
US12024553B2 (en) * 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies

Similar Documents

Publication Publication Date Title
JP2024016177A5 (enExample)
US20240182573A1 (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
JP2020518599A5 (enExample)
CN110418803B (zh) 抗rsv单克隆抗体配制品
JP2020518600A5 (enExample)
JP6647208B2 (ja) 抗ｉｌ−１７抗体、その生産および使用のための方法
JP2022079549A5 (enExample)
CN111971062A (zh) 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
JP2023109942A5 (enExample)
JP2020518598A5 (enExample)
JP2018535650A5 (enExample)
FI4045533T3 (fi) Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
JP2018188437A5 (enExample)
JP2019163319A5 (enExample)
JP2019031565A5 (enExample)
HRP20201345T1 (hr) Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba
JP2017160208A5 (enExample)
JP2018505177A5 (enExample)
JP2021527640A5 (enExample)
JP2015120706A5 (enExample)
CN112741804A (zh) 含有抗pd-l1抗体的稳定制剂
JP2025032102A5 (enExample)
KR20160079890A (ko) 항체-약물 접합체 동결건조 제제
JP2024508762A5 (enExample)
HK1199463A1 (en) Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile